Similar Search Results

The Cost of HIV Treatment and Care: A Global Review

Beck, Eduard J.; Miners, Alec H.; Tolley, Keith - In: PharmacoEconomics 19 (2001) 1, pp. 13-39

This review of published studies on the costs of HIV treatment and care describes some of the recent developments that have influenced these costs in industrialised and industrialising countries, especially within the context of changing drug treatments. Some of the different approaches to...

Persistent link: https://www.econbiz.de/10005404774

Economic Issues in the Prevention of Vertical Transmission of HIV

Ades, A.E.; Ratcliffe, Julie; Gibb, Diana M.; Sculpher, … - In: PharmacoEconomics 18 (2000) 1, pp. 9-22

conceptions of pre-test counselling. The demonstration that nevirapine reduces transmission risk at a low cost has transformed the …

Persistent link: https://www.econbiz.de/10005404917

Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia

Mauskopf, Josephine A.; Cates, Sheryl C.; Griffin, Adrian D. - In: PharmacoEconomics 17 (2000) 6, pp. 611-620

Objective: To use data from a clinical trial of zanamivir, a new antiviral drug, to estimate the costs and effectiveness of alternative treatment strategies for a high-risk population in Australia visiting a physician for treatment of influenza or influenza-like illness within 36 hours of...

Persistent link: https://www.econbiz.de/10005590504

Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation: Comparing Valaciclovir Prophylaxis with Current Practice

Mauskopf, Josephine A.; Richter, Anke; Annemans, Lieven; … - In: PharmacoEconomics 18 (2000) 3, pp. 239-251

Background: Cytomegalovirus (CMV) disease may occur following renal transplantation and has been shown to have health and cost consequences in this setting. Objective: To compare the cost effectiveness of different CMV management strategies for renal transplant patients: prophylaxis with (i)...

Persistent link: https://www.econbiz.de/10005449009

Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS

Kempen, John H.; Frick, Kevin D.; Jabs, Douglas A. - In: PharmacoEconomics 19 (2001) 12, pp. 1199-1208

Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior...

Persistent link: https://www.econbiz.de/10005404898

Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B

Crowley, Steven J.; Tognarini, David; Desmond, Paul V.; … - In: PharmacoEconomics 17 (2000) 5, pp. 409-427

the introduction of lamivudine for chronic hepatitis B. Design: The analysis used a 2-step modelling approach. A decision … short term, more patients seroconverted when lamivudine was available, with an incremental cost-effectiveness ratio of 3341 … Australian dollars ($A) per additional seroconversion. In the long term, the introduction of lamivudine increased life expectancy …

Persistent link: https://www.econbiz.de/10005405004

The Economics of HIV Vaccines: Projecting the Impact of HIV Vaccination of Infants in Sub-Saharan Africa

Bos, Jasper M.; Postma, Maarten J. - In: PharmacoEconomics 19 (2001) 9, pp. 937-946

Objectives: 1. To project vaccine parameters, economic consequences and market size associated with HIV-1 vaccination of infants in sub-Saharan Africa through the Expanded Program on Immunisation (EPI); and 2. to assess threshold values for price and effectiveness. Study design and methods:...

Persistent link: https://www.econbiz.de/10005449097

Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis

Attanasio, Ermanno; Russo, Pierluigi; Carunchio, Gabriella - In: PharmacoEconomics 19 (2001) 1, pp. 57-68

Background: In a recent clinical trial, dermatan sulfate was found to be more effective than unfractionated heparin (UFH), but equally well tolerated, for the prevention of deep vein thrombosis (DVT) after major surgery for cancer. Objective: To perform a cost-effectiveness analysis of dermatan...

Persistent link: https://www.econbiz.de/10005243139

Cost-Effectiveness Analysis of Pneumococcal Vaccination of Adults and Elderly Persons in Belgium

De Graeve, Diana; Lombaert, Geert; Goossens, Herman - In: PharmacoEconomics 17 (2000) 6, pp. 591-601

Objective: To analyse the direct medical costs and effectiveness of vaccinating adults aged between 18 and 64 years and elderly persons =65 years of age with the 23-valent pneumococcal polysaccharide vaccine. Design and setting: This was a decision-analytic modelling study from the societal...

Persistent link: https://www.econbiz.de/10005404788

Influenza: Cost of Illness and Considerations in the Economic Evaluation of New and Emerging Therapies

Cram, Peter; Blitz, Susan G.; Monto, Arnold; Fendrick, … - In: PharmacoEconomics 19 (2001) 3, pp. 223-230

Influenza infection has been a burden to humans for thousands of years. Despite the fact that epidemics could be predicted with regularity, the lack of available prevention or treatment measures left humankind vulnerable to the harmful effects of this ubiquitous virus. While the pandemics of...

Persistent link: https://www.econbiz.de/10005590304